Prognostic Impact of Deletions of Derivative Chromosome 9 in Patients With Chronic Myelogenous Leukemia Treated With Nilotinib or Dasatinib

BACKGROUND: Deletions of derivative chromosome 9 are a poor prognostic factor in patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem cell transplantation. Imatinib may overcome the adverse prognostic impact of deletions of derivative chromosome 9. METHODS: A st...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer
Main Authors: Quintás-Cardama, Alfonso, Kantarjian, Hagop, Shan, Jianqin, Jabbour, Elias, Abruzzo, Lynne V., Verstovsek, Srdan, Garcia-Manero, Guillermo, O'Brien, Susan, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4324753/
https://ncbi.nlm.nih.gov/pubmed/21523765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26147
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares